Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 15 January 2005, Vol. 105, No. 2, pp. 542-544.
Prepublished online as a Blood First Edition Paper on September 14, 2004; DOI 10.1182/blood-2004-06-2096.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2004-06-2096v1
105/2/542    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Studt, J.-D.
Right arrow Articles by Lämmle, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Studt, J.-D.
Right arrow Articles by Lämmle, B.
Related Collections
Right arrow Hemostasis, Thrombosis, and Vascular Biology
Right arrow Brief Reports
Right arrow Clinical Trials and Observations
Right arrowRelated Article in Blood Online
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Brief report

Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin

Jan-Dirk Studt, Johanna A. Kremer Hovinga, Gerhard Antoine, Martin Hermann, Manfred Rieger, Friedrich Scheiflinger, and Bernhard Lämmle

From the Department of Hematology and Central Hematology Laboratory, Inselspital, University Hospital, Bern, Switzerland; Baxter BioScience, Orth, Austria; and the Department of Pediatrics, University Hospital, Tübingen, Germany.

Severe ADAMTS13 deficiency in thrombotic thrombocytopenic purpura (TTP) is either constitutional and caused by ADAMTS13 mutations, or acquired and most often due to ADAMTS13 inhibitory autoantibodies. In strongly hemolytic serum of a pediatric patient, diagnosed with TTP postmortem, ADAMTS13 activity was less than 3%. Both parents had an ADAMTS13 activity of approximately 50%. Sequencing of the ADAMTS13 gene revealed an intronic 687-2A>G substitution affecting exon 7, homozygous in the propositus and heterozygous in both parents, confirming constitutional ADAMTS13 deficiency. ADAMTS13 activity of normal plasma was inhibited by incubation with the propositus' serum, suggesting alloantibody formation to ADAMTS13. However, immunoglobulin purified from serum had no ADAMTS13 inhibitory effect, whereas the immunoglobulin-depleted hemolytic serum inhibited ADAMTS13 activity of normal plasma, suggesting an inhibitory effect of hemolysis products. Incubation of hemoglobin, recombinant and from lysed erythrocytes, with normal plasma revealed an ADAMTS13 inhibitory effect at hemoglobin concentrations of 2 g/L or higher.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Hemoglobin versus ADAMTS13
David Motto
Blood 2005 105: 436-437. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 HypertensionHome page
B.-J. H. van den Born, N. V. van der Hoeven, E. Groot, P. J. Lenting, J. C.M. Meijers, M. Levi, and G. A. van Montfrans
Association Between Thrombotic Microangiopathy and Reduced ADAMTS13 Activity in Malignant Hypertension
Hypertension, April 1, 2008; 51(4): 862 - 866.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Ferrari, F. Scheiflinger, M. Rieger, G. Mudde, M. Wolf, P. Coppo, J.-P. Girma, E. Azoulay, C. Brun-Buisson, F. Fakhouri, et al.
Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity
Blood, April 1, 2007; 109(7): 2815 - 2822.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
R. F. Machado, A. Anthi, M. H. Steinberg, D. Bonds, V. Sachdev, G. J. Kato, A. M. Taveira-DaSilva, S. K. Ballas, W. Blackwelder, X. Xu, et al.
N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease.
JAMA, July 19, 2006; 296(3): 310 - 318.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Rieger, P. M. Mannucci, J. A. K. Hovinga, A. Herzog, G. Gerstenbauer, C. Konetschny, K. Zimmermann, I. Scharrer, F. Peyvandi, M. Galbusera, et al.
ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases
Blood, August 15, 2005; 106(4): 1262 - 1267.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
R. P. Rother, L. Bell, P. Hillmen, and M. T. Gladwin
The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin: A Novel Mechanism of Human Disease
JAMA, April 6, 2005; 293(13): 1653 - 1662.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020